Axsome Therapeutics, Inc. AXSM R2KR3KPHARMA
Company Overview
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Why Investors Should Care
Revenue has grown at a 133.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $638.50M (+65.5% YoY); net profit $-183.17M.
- Trailing 12 Months Year-on-year growth — revenue +57.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 133.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 133.68% |
| 1 Year: | 57.40% |
Stock Price Performance
| 1 Year: | +67.39% |
| 6 Months: | +27.32% |
| 3 Months: | -11.04% |
| 1 Month: | -1.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)43.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 133.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AXSM Axsome Therapeutics, Inc. R2KR3KPHARMA | 206.68 | -55.56 | $10.64B | 0.00% | -54.42% | - | 133.68% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.82M | 16.85M | 94.58M | 46.70M | 57.79M | 75.00M | 87.17M | 104.76M | 121.46M | 150.04M | 170.99M | 196.00M | 191.20M | 218.38M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.79M | 13.45M | 11.91M | 12.33M | 14.72M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.67M | 136.59M | 159.08M | 183.67M | 176.48M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 167.14M | 181.41M | 192.00M | 219.69M | 239.25M | - |
| Operating Income | 2.02M | 3.15M | 5.88M | 6.83M | 7.21M | 7.63M | 7.67M | 6.75M | 6.30M | 6.44M | -7.16M | -7.99M | -8.24M | 9.45M | -10.42M | -13.45M | -18.95M | - | -32.49M | -17.78M | -21.13M | - | -27.84M | -30.85M | -33.41M | -38.29M | -39.18M | -42.41M | -6.37M | -65.06M | -62.12M | -67.28M | -78.05M | -62.62M | -55.47M | -44.82M | -32.92M | -36.02M | -62.77M | -49.65M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.85M | -44.85M | -43.70M | -24.68M | -60.99M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.43M | 1.83M | 1.12M | 1.17M | 1.19M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -59.41M | -48.93M | -47.23M | -28.13M | -64.54M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | -960.00K | 0 | 430.00K | 0 | - |
| Net Income | -4.58M | -3.36M | -5.87M | -6.81M | -7.19M | -7.33M | -8.00M | -7.08M | -6.43M | -7.43M | -4.81M | -8.28M | -8.28M | -9.60M | -10.64M | -13.76M | -19.14M | -24.81M | -32.48M | -18.33M | -22.92M | -29.16M | -29.26M | -32.28M | -34.88M | -39.63M | -41.44M | -44.82M | -11.22M | -67.17M | -62.20M | -68.36M | -79.34M | -64.60M | -59.41M | -47.97M | -47.23M | -28.56M | -64.54M | -51.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.86 | -0.93 | -1.06 | -1.06 | -1.07 | -0.26 | -1.54 | -1.32 | -1.44 | -1.67 | -1.34 | -1.22 | -0.97 | -0.94 | -0.56 | -1.26 | -0.99 |
| R&D Expense | 1.52M | - | 4.53M | 5.30M | 5.57M | - | 5.99M | 5.01M | 4.47M | - | 4.75M | 5.55M | 6.04M | - | 7.60M | 11.00M | 15.84M | - | 27.52M | 10.54M | 14.80M | - | 16.60M | 14.50M | 13.18M | 12.59M | 15.79M | 14.88M | 17.79M | 20.58M | 28.77M | 36.83M | 49.85M | 45.39M | 44.78M | 49.54M | 40.16M | - | 52.68M | 46.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 50.04M | 270.60M | 385.69M | 638.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | 5.20M | 26.07M | 33.30M | 47.48M |
| Gross Profit | - | - | - | - | - | - | - | - | 44.84M | 244.53M | 352.39M | 591.02M |
| Operating Expenses | - | - | - | - | - | - | - | - | 221.34M | 427.44M | 604.83M | 760.25M |
| Operating Income | -5.67M | -9.20M | -27.54M | -27.16M | -32.85M | -67.25M | -99.14M | - | -176.50M | -182.91M | -252.44M | -169.24M |
| EBITDA | - | - | - | - | - | - | - | - | -175.40M | -224.99M | -272.60M | -168.08M |
| Interest Expense | - | - | - | - | - | - | - | - | 7.33M | 6.45M | 6.57M | 6.56M |
| Pretax Income | - | - | - | - | - | - | - | - | -187.13M | -238.28M | -287.13M | -183.70M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | 960.00K | 85.00K | -530.00K |
| Net Income | -6.00M | -12.21M | -27.20M | -28.94M | -30.97M | -68.35M | -102.90M | - | -187.13M | -239.24M | -287.22M | -183.17M |
| Diluted EPS | - | - | - | - | - | - | -2.77 | - | -4.60 | -5.27 | -5.99 | -3.68 |
| R&D Expense | 4.28M | 6.78M | 21.20M | 19.96M | 23.50M | 53.65M | 70.24M | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 49.08M | 38.21M | 35.56M | 15.38M | 220.55M | 186.13M | - | 331.48M | 588.24M | 568.50M | 689.80M |
| Current Assets | - | - | - | - | - | - | - | - | - | 245.64M | 504.26M | 485.06M | 588.99M |
| Cash & Equivalents | - | - | - | - | - | - | 219.97M | 183.88M | - | 200.84M | 386.19M | 315.35M | 322.93M |
| Inventory | - | - | - | - | - | - | - | - | - | 4.32M | 15.13M | 15.73M | 27.94M |
| Receivables | - | - | - | - | - | - | - | - | - | 37.70M | 94.82M | 142.00M | 224.46M |
| Total Liabilities | - | - | 2.63M | 16.64M | 18.84M | 14.44M | 41.83M | 72.34M | - | 221.92M | 397.26M | 511.48M | 601.51M |
| Current Liabilities | - | - | 2.63M | 7.17M | 12.18M | 10.82M | 24.49M | 23.44M | - | 96.56M | 138.85M | 230.10M | 378.84M |
| Long Term Debt | - | - | - | 9.47M | 6.66M | 3.62M | 17.33M | 48.32M | - | 94.26M | 178.07M | 180.71M | 117.75M |
| Total Debt | - | - | - | - | - | - | - | - | - | 94.68M | 186.37M | 192.96M | 218.11M |
| Total Equity | -2.03M | -3.20M | 46.44M | 21.57M | 16.72M | 937.92K | 178.72M | 113.79M | - | 109.56M | 190.98M | 57.02M | 88.30M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 43.50M | 47.35M | 48.67M | 50.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.60M | -7.44M | -21.28M | -26.47M | -30.05M | -46.38M | -78.46M | - | -116.51M | -145.08M | -128.41M | -93.41M |
| Investing Cash Flow | - | -20.20K | -104.56K | -9.90K | -32.70K | -16.12K | -45.89K | - | -53.70M | -582.00K | -270.00K | -480.00K |
| Financing Cash Flow | 5.13M | 52.88M | 9.97M | 23.88M | 10.03M | 252.39M | 42.41M | - | 284.58M | 331.01M | 57.84M | 101.47M |
| Capital Expenditure | - | -20.20K | -104.56K | -9.90K | -32.70K | -16.12K | -45.89K | - | -702.00K | -582.00K | -270.00K | -480.00K |
| Free Cash Flow | - | -7.46M | -21.39M | -26.48M | -30.09M | -46.39M | -78.50M | - | -117.21M | -145.66M | -128.68M | -93.89M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 114.37M | 185.35M | -70.84M | 7.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 89.6% | 90.4% | 91.4% | 92.6% |
| Operating Margin % | - | - | - | - | - | - | - | - | -352.7% | -67.6% | -65.5% | -26.5% |
| Net Margin % | - | - | - | - | - | - | - | - | -374.0% | -88.4% | -74.5% | -28.7% |
| ROE % | 187.4% | -26.3% | -126.1% | -173.1% | -3,301.5% | -38.2% | -90.4% | - | -170.8% | -125.3% | -503.8% | -207.5% |
| ROCE % | - | -19.8% | -88.7% | -116.2% | -720.7% | -34.3% | -60.9% | - | -75.1% | -40.7% | -74.6% | -54.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.93% | 3.10M | $617.70M |
| 2 | Vanguard Portfolio Management LLC | 3.79% | 1.98M | $394.76M |
| 3 | Vanguard Capital Management LLC | 3.75% | 1.97M | $391.09M |
| 4 | Invesco Ltd. | 3.19% | 1.67M | $332.70M |
| 5 | FMR, LLC | 2.94% | 1.54M | $306.32M |
| 6 | Geode Capital Management, LLC | 1.85% | 967.17K | $192.49M |
| 7 | Morgan Stanley | 1.54% | 804.08K | $160.03M |
| 8 | State Street Corporation | 1.50% | 785.66K | $156.36M |
| 9 | Deep Track Capital, Lp | 1.34% | 700.00K | $139.31M |
| 10 | Two Sigma Investments, LP | 1.28% | 669.48K | $133.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AXSM
Axsome Therapeutics (AXSM) Stock Looks Like A Bargain On Its 7x Five Year Run - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOTXBIeHFoRzNRMWVfQmZWQURraVF3bzJIMktmdnEwV3RVYm0wTnQ2U3YxU3BycnpjXzRPcnl5VWQ3UW0tWWN5MGNDN1dNNjQwT29KZFMzNE5CaWlRZVlSS3NWcHdCTUt6S0NWZDUyQU9ZQ2NBUXBaN3ZWWk8xRVRUaE5CajdYMmNjYXVhbk…
33,554 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Readystate Asset Management LP - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPZUlIVHFjbzlrVXFydTI0dWVwYmlkTUw3Nk1VWVEzc1FnbVNsT1ZvRVN3dmk1MjQ1bDdIUVZEUlc3bmpXZk1CVHFzbTQ5cUMzdHp4ZHpJd3drS09acV8zUmlaTGNoMjRKUm1Ma0Jzbm1YcDFCSVAxYUtfTGdKUVVkZXVVb3VscUY2VlQ2el…
Planned $2.1M Axsome Therapeutics (AXSM) stock sale set under pre-arranged trading plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOUERfQjVJeXdRd1Z6aTkxd2RNYjRScWJkTGFTTVdKUXI2bkpDWkZjWjVrY0FIQnh3YU1Rc1padHNDTTN0YmF1V01EMU1HTGE1dzJQUkNxT3pfOGF1MXhzSkVkdHlnSlpmTDZpMVNXNzdSSmFLYUt0dW5COW02eUVBRDJLbDJiTkZNMW1jR3…
Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPUjFNaTdqUTMwbk5nZzlrMHBKbkRNU3kyQWlTUk9FbVAwcGlUYy05QlFvbWFPUmMyeHBaRkowMVZMLTlib3N5WFQ1QVVwZnhqcXRfS1JHWFdraEVqNHVWd1BBZFo3VjczUGNuYUlPWkRCaGJ0ZVNENFlyWTF4OFlhTE1VTWZzcWpQUjNsOU…
Why Axsome Therapeutics (AXSM) Stock Is Down Today - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPM0ZjUDV0UUlhZDJrTXJxc2otc0Rqd1hubklqSTN2MUNfUW5FZ0ZtMkJSMUJab1FzSl9ieUlYRUhYZ0RPSDZ6QXI3em1EVlpSaU5WZGhwRjRTZ1M2ZGt0ZUR1ZktNZFdka2I4SUpWX3RjcF85LTluNzJFc2RyeE9sZkw3OEhuMXowbXdXSm…
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Gem with 43% Upside Potential - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPSnpWNnZxLUlUU1MwT3JNR2JmQk5yaU8tdVpXd1FSaXJBVXROSUt4dzFyWnR0RzRPNHVLZjloWlc2WFVzZGdDaEU1Q3lpOElnN1RhLUFlNnI1d2Z2NUNVVjY4Z2x0VWl0a3RKRTlwcms4d0ZhOTdDSU5SbXFSQUdyaEdrTlBnTU5QclhHUn…
AXSM — Frequently Asked Questions
What is the current share price of Axsome Therapeutics, Inc. (AXSM)?
As of 2026-09-07 16:24 PDT, Axsome Therapeutics, Inc. (AXSM) trades at $206.68 on NasdaqGM. Its 52-week range is $114.10 to $255.17.
What is the market capitalisation of AXSM?
Axsome Therapeutics, Inc. (AXSM) has a market capitalisation of $10.64B on NasdaqGM.
What is the P/E ratio of AXSM?
AXSM trades at a trailing price-to-earnings (P/E) ratio of -55.56. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 200.32.
Is AXSM a good stock to buy?
This page provides a data-driven analysis of Axsome Therapeutics, Inc. (AXSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.